ArticleDiscover oncology2025
Multi-omics analysis identified LGALS1 (Galectin-1) as a novel therapeutic target for clear cell renal cell carcinoma via targeting epithelial or endothelial cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor.Experimental hematology & oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSince the pathophysiology of clear cell renal cell carcinoma (ccRCC) was still unknown, finding novel therapeutic targets to support current treatment approaches was crucial.
methodsWe conducted an RNA-Sequencing analysis using data from the TCGA-KIRC dataset, with our own clinical data serving as validation. Kaplan–Meier survival curves, univariate and multivariate studies of overall survival, and differential expression analysis were all used. Furthermore, we explored the correlation between LGALS1 (Galectin-1) and clinical characteristics in ccRCC patients by leveraging proteomics data from the CPTAC analysis. Additionally, the Single-cell RNA-Sequencing (scRNA-Seq) analysis elucidated the cellular landscape of LGALS1 using the GSE159115 database, complemented by pathway enrichment analysis via GO and KEGG datasets. Lastly, we performed an immunohistochemistry (IHC) analysis on ccRCC tissue microarrays and scored the staining intensity. While p < 0.05 was used for other analyses, p < 0.1 was deemed significant in multivariate analysis.
resultsAs shown in TCGA and confirmed in our clinical data, higher LGALS1 expression in ccRCC was associated with a bad prognosis. Proteomics analysis in the CPTAC dataset revealed that LGALS1 levels were statistically significant across different grade and stage groups of patients. The high expression was confirmed on the IHC chip, with tumor tissue displaying a higher staining intensity score. Additionally, scRNA-Seq analysis identified that the differential expression of LGALS1 primarily occurred in endothelial and epithelial cells, along with associated signaling pathways.
conclusionsWe performed a multi-omics analysis using transcriptomics, proteomics, single-cell omics, and our clinical data, confirming LGALS1 as a possible target for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.